MergerJun 5, 2026, 04:37 PM
Beacon Topco S-4 for Barinthus Bio, Clywedog merger effective
AI Summary
Beacon Topco, Inc. filed its Q1 2026 10-Q, reporting no operational activities, assets, or liabilities for the period ended March 31, 2026. The company was formed solely for the purpose of consummating a business combination with Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. The SEC declared its Form S-4 registration statement effective on April 22, 2026, a key step towards the merger. Upon closing, Barinthus Bio shareholders are expected to own approximately 34% and Clywedog stockholders 66% of the combined entity, which will be renamed "Clywedog Therapeutics Holdings, Inc." and listed on Nasdaq under "CLYD".
Key Highlights
- Beacon Topco reported no assets, liabilities, revenues, or expenses for Q1 2026.
- The company was formed on September 24, 2025, for a business combination.
- The SEC declared its Form S-4 registration statement effective on April 22, 2026.
- Beacon Topco will acquire Barinthus Bio and Clywedog Therapeutics, Inc.
- Barinthus Bio shareholders are expected to own approximately 34% of the combined company.
- Clywedog stockholders are expected to own approximately 66% of the combined company.
- Upon closing, Beacon Topco will be renamed "Clywedog Therapeutics Holdings, Inc.".
- The combined entity will be listed on Nasdaq under the ticker symbol "CLYD".
Price Impact
More from CLYD